Akers' set to double output with flotation proceeds
This article was originally published in Clinica
Executive Summary
US POC diagnostics company Akers Biosciences says it will double its diagnostic kit manufacturing output to 36 million units annually with the proceeds from its recent UK AIM listing. The company raised £3.4 million ($4.9 million) this month, capitalising it at £54 million, with its 2.25 million share issue. Kit production will "expand across the street" at the company's New Jersey plant, where new facilities will be equipped, said CEO Ray Akers.